Genprex

Monthly Archives: September 2018

Genprex™ Taps Aldevron to Supply TUSC2 Plasmid DNA for Oncoprex Clinical Development Program

AUSTIN, Texas & CAMBRIDGE, Mass. & FARGO, N.D.–(BUSINESS WIRE)–Sep. 27, 2018– Genprex, Inc. (NASDAQ:GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, has signed an agreement with Aldevron, a leading contract manufacturing organization, to supply TUSC2 (Tumor Suppressor Candidate2) plasmid DNA for use in Genprex’s clinical development program evaluating its immunogene therapy Oncoprex™ for the treatment of non-small cell lung cancer….

Read More

Genprex CEO Updates Investors on Recent $10M Capital Raise and Progress of Oncoprex

…AUSTIN, Texas & CAMBRIDGE, Mass.–Sept. 6, 2018– Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, updates Proactive Investors on company operations in the last few months, notably raising $10 million to be used toward continuing the company’s clinical trial of Oncoprex.

Read More